Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 84
Filter
1.
Int Immunopharmacol ; 118: 110077, 2023 May.
Article in English | MEDLINE | ID: mdl-37011499

ABSTRACT

Colon cancer was the second leading cause of cancer-related deaths in Japan in 2019. The effects of geniposide isolated from Gardenia jasminoides fructus (Rubiaceae) on the azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced growth of colon tumors and changes in interleukin (IL)-1 ß, monocyte chemoattractant protein (MCP)-1, IL-10, and programmed cell death-1 (PD-1) levels in the colon were investigated. The intraperitoneal administration of AOM (10 mg/kg) on days 0 and 27 induced colorectal carcinogenesis. Free access to 1% (w/v) DSS drinking water was given to mice on days 7-15, 32-33, and 35-38. Geniposide (30 and 100 mg/kg) was orally administered on days 1-16, discontinued for 11 days (days 16 to 26), and then administered again on days 27-41. Colonic levels of cytokines, chemokine, and PD-1 were measured using by enzyme-linked immunosorbent assay (ELISA). Increases in colorectal tumor numbers and areas were significantly inhibited by geniposide. In addition, geniposide (100 mg/kg) reduced colonic levels of IL-1 ß, MCP-1, PD-1 and IL-10 by 67.4, 57.2, 100%, and 100% respectively. Cyclooxygenase (COX)-2- and thymocyte selection high mobility group box proteins (TOX/TOX2)-positive cell numbers were significantly reduced by geniposide. Geniposide (30 and 100 mg/kg) decreased the phosphorylation of signal transducer and activator of transcription 3 (STAT3) expressions in immunohistochemical analysis by 64.2 and 98.2%, respectively. Thus, the inhibitory effects of geniposide on colon tumor growth may be associated with reductions in the colonic levels of IL-1 ß, MCP-1, IL-10, and PD-1 via the down-regulated expression of COX-2 and TOX/TOX2 through the inhibition of Phospho-STAT3 expression (in vivo and in vitro).


Subject(s)
Colitis , Colonic Neoplasms , Animals , Mice , Cyclooxygenase 2 , Azoxymethane , Interleukin-10 , Interleukin-1beta/adverse effects , Dextran Sulfate , Chemokine CCL2 , Programmed Cell Death 1 Receptor , Thymocytes , Colonic Neoplasms/chemically induced , Colonic Neoplasms/drug therapy , Colonic Neoplasms/metabolism , Colitis/chemically induced , Mice, Inbred C57BL
2.
Eur J Pharmacol ; 947: 175680, 2023 May 15.
Article in English | MEDLINE | ID: mdl-36990263

ABSTRACT

Colon cancer was the second leading cause of cancer-related death in 2019. We herein investigated the effects of acertannin containing Acer species on azoxymethane (AOM)/dextran sulfate sodium (DDS)-induced colon cancer growth and changes in the colonic levels of interleukin (IL)-1ß, monocyte chemoattractant protein (MCP)-1, IL-10, and programmed cell death-1 (PD-1). Colorectal carcinogenesis was induced by an intraperitoneal injection of AOM (10 mg/kg) on days 0 and 27. Mice were given 1% (w/v) DSS drinking water ad libitum on days 7-14, 32-33, and 35-38. Acertannin (30 and 100 mg/kg) was orally administered on days 1-16, discontinued for 11 days (days 16-26), and then administered again on days 27-41. The colonic levels of cytokines, a chemokine, and PD-1 were measured using the respective ELISA kits. The number and area of tumors in mice treated with acertannin (100 mg/kg) decreased by 53.9 and 63.1%, respectively. Furthermore, the colonic levels of IL-1ß, MCP-1, IL-10, and PD-1 showed reductions of 57.3, 62.9, 62.8, and 100%, respectively, while the numbers of cyclooxygenase-2 (COX-2)-, thymocyte selection-associated high mobility group box proteins (TOX)/TOX2-, PD-1-, and signal transducer and activator of transcription 3 (STAT3) phosphorylation-positive numbers decreased by 79.6, 77.9, 93.8, and 100%, respectively. In conclusion, the inhibitory effects of acertannin on AOM/DSS-induced colon tumor growth appear to be associated with reductions in the colonic levels of IL-1ß, MCP-1, IL-10, and PD-1 through the down-regulated expression of COX-2 and TOX/TOX2 in the tumor microenvironment.


Subject(s)
Colonic Neoplasms , Tannins , Animals , Mice , Azoxymethane/toxicity , Chemokine CCL2/metabolism , Colon , Colonic Neoplasms/chemically induced , Colonic Neoplasms/prevention & control , Colonic Neoplasms/metabolism , Cyclooxygenase 2/metabolism , Dextran Sulfate/toxicity , Interleukin-10/metabolism , Interleukin-1beta/metabolism , Mice, Inbred C57BL , Programmed Cell Death 1 Receptor/metabolism , Tumor Microenvironment , Tannins/pharmacology
3.
Planta Med ; 89(7): 746-753, 2023 Jun.
Article in English | MEDLINE | ID: mdl-36796450

ABSTRACT

The present study investigates the effects of acertannin on colitis induced by dextran sulfate sodium (DSS) and changes in the colonic levels of the cytokines interleukin (IL)-1ß, IL-6, IL-10, IL-23, tumor necrosis factor (TNF)-α, the chemokine monocyte chemoattractant protein (MCP)-1, and vascular endothelial growth factor (VEGF).We examine the following: inflammatory colitis was induced in mice by 2% DSS drinking water given ad libitum for 7 days. Red blood cell, platelets, and leukocyte counts and hematocrit (Ht), hemoglobin (Hb), and colonic cytokine and chemokine levels were measured. The disease activity index (DAI) was lower in DSS-treated mice orally administered acertannin (30 and 100 mg/kg) than in DSS-treated mice. Acertannin (100 mg/kg) inhibited reductions in the red blood cell count and Hb and Ht levels in DSS-treated mice. Acertannin prevented DDS-induced mucosal membrane ulceration of the colon and significantly inhibited the increased colonic levels of IL-23 and TNF-α. Our findings suggest that acertannin has potential as a treatment for inflammatory bowel disease (IBD).


Subject(s)
Colitis , Tumor Necrosis Factor-alpha , Mice , Animals , Tumor Necrosis Factor-alpha/metabolism , Dextran Sulfate/adverse effects , Interleukin-23/adverse effects , Interleukin-23/metabolism , Mice, Inbred C57BL , Vascular Endothelial Growth Factor A/adverse effects , Vascular Endothelial Growth Factor A/metabolism , Colitis/chemically induced , Colitis/drug therapy , Colon/pathology , Cytokines/metabolism , Disease Models, Animal
4.
Phytomedicine ; 100: 154076, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35378414

ABSTRACT

BACKGROUND: Colorectal cancer was the second leading cause of mortality in 2019 and the number of new colorectal cancer cases was the highest in 2018 and 2019 in Japan. PURPOSE: The present study investigated the inhibitory effects of 2(S)-2',5,6',7-tetrahydroxyflavanone and 2 (R), 3(R)-2',3,5,6'-7-pentahydroxyflavanone on the incidence and growth of tumors in azoxymethane (AOM) plus dextran sulfate sodium (DSS)-treated mice. METHODS: The intraperitoneal administration of AOM (10 mg/kg) on day 0 induced colorectal carcinogenesis. Mice were given free and unlimited access to drinking water containing 1.5% (w/v) DSS on days 5 - 8, 30 - 33, and 56 - 57. They were orally administered tetra- and penta-hydroxyflavanones (10 and 30 mg/kg) for 10, 11, and 14 days followed by discontinuation intervals of 20 and 15 days. Cytokine, chemokine, programmed cell death-1 (PD-1), cyclooxygenase (COX)-2, and thymocyte selection-associated high mobility group box protein (TOX)/TOX2 expression levels were measured using their respective ELISA kits and an immunohistochemical analysis. RESULTS: The number and area of tumors decreased by 60.6 and 72.9% in mice administered 10 mg/kg tetra- and pentahydroxyflavanones, respectively, with reductions of 95.0 and 87.0% in Ki-67-positive cells, 91.7 and 92.7% in COX-2-postive cells, and 83.1 and 93.8% in TOX/TOX2-positive cells, respectively, in the colon. On the other hand, two tera- and pentahydroxyflavanone had no effect on p53 (a tumor suppressor by cell cycle arrest and apoptosis)-positive cells. The administration of 10 mg/kg tetra- and pentahydroxyflavanones to AOM/DSS-treated mice also resulted in decreases of 59.5 and 42.5% in IL-10 levels and 58.1 and 93.9% in PD-1 levels, respectively, in the colon. CONCLUSION: The inhibitory effects of tetra- and pentahydroxyflavanones on the growth of colon tumors in AOM/DSS-treated mice appear to be associated with decreases in the colon levels of IL-10 and PD-1 through the down-regulated expression of COX-2 and CD8+ T-cell exhaustion by TOX/TOX2 in the tumor microenvironment.


Subject(s)
Colitis-Associated Neoplasms , Colitis , Colonic Neoplasms , Animals , Apoptosis , Azoxymethane/toxicity , Colitis/chemically induced , Colitis/drug therapy , Colitis/metabolism , Colon/pathology , Colonic Neoplasms/chemically induced , Colonic Neoplasms/drug therapy , Colonic Neoplasms/prevention & control , Cyclooxygenase 2/metabolism , Dextran Sulfate/adverse effects , HMGB Proteins/metabolism , HMGB Proteins/pharmacology , Interleukin-10/metabolism , Mice , Mice, Inbred C57BL , Programmed Cell Death 1 Receptor/metabolism , Scutellaria baicalensis , Thymocytes/metabolism , Thymocytes/pathology , Tumor Microenvironment
5.
Nutr Cancer ; 74(6): 2184-2195, 2022.
Article in English | MEDLINE | ID: mdl-34622729

ABSTRACT

AIM: The effects of 3,5,3',4'-tetrahydroxystilbene (piceatannol) on azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colon cancer growth and changes in IL-1ß, IL-6, tumor necrosis factor-α (cytokines), MCP-1, vascular endothelial growth factor, and PD-1 colon levels were investigated herein. METHODS: AOM (10 mg/kg, i.p.) on day 0 induced colorectal carcinogenesis. On day 3, mice were provided with water containing 1.5% (w/v) DSS ad libitum for 3 day, and this 3-day drinking protocol was repeated twice. Piceatannol (5 and 12.5 mg/kg, twice daily) was orally administered to mice for 7-, 7-, 7-, and 6-day and then discontinued for 14-, 15-, and 16-day. Cytokines, chemokine, and PD-1 colon levels were measured by the respective ELISA kits. RESULTS: In mice administered piceatannol (12.5 mg/kg), the tumor number, tumor area, and Ki-67-positive cell numbers decreased by 30.1%, 57.2%, and 89.1%, respectively, colon MCP-1 and PD-1 levels showed reductions of 43.8% and 70.9%, respectively, and COX-2-positive cell numbers declined by 60.2%. CONCLUSIONS: The inhibitory effects of piceatannol on AOM/DSS-induced colon tumor growth appear to be associated with reductions in colon MCP-1 and PD-1 levels through the downregulated expression of COX-2 in the tumor microenvironment.


Subject(s)
Colitis , Colonic Neoplasms , Administration, Oral , Animals , Azoxymethane/toxicity , Colitis/chemically induced , Colon/metabolism , Colonic Neoplasms/chemically induced , Colonic Neoplasms/drug therapy , Colonic Neoplasms/metabolism , Cyclooxygenase 2/metabolism , Cytokines/metabolism , Dextran Sulfate/toxicity , Disease Models, Animal , Mice , Mice, Inbred C57BL , Programmed Cell Death 1 Receptor/metabolism , Stilbenes , Tumor Microenvironment , Vascular Endothelial Growth Factor A/metabolism
6.
Zookeys ; 1123: 187-204, 2022.
Article in English | MEDLINE | ID: mdl-36762037

ABSTRACT

We evaluated the molars in Anderson's red-backed vole (n = 114) from the Kii Peninsula of Honshu, Japan. Two of the specimens are considered extremely old aged based on their dimensions and on the loss of alveolar capsules of M2, and a third one is also old based on its strongly worn left M3 and M1. Of the former two individuals, one showed an incipient closure of re-entrant angles at its basal end, as estimated from the difference between the occlusal patterns of the occlusal and basal surfaces of the left M2. The latter individual also showed a complete closure of the basal end in the left M3. These patterns differ from incipient roots observed in other vole taxa but were similar to a previous example of incipient roots in Anderson's red-backed vole. Therefore, we suggest that molar roots in this species form at an extremely late age or by strong wear. Root formation in molars is considered an important diagnostic character, as Eothenomys molars lack roots, while Craseomys molars develop roots at a late age. However, this dental character may be particularly difficult to assess in voles under natural conditions. Considering previous phylogenetic findings based on molecular analyses, Craseomys is the most appropriate genus for Anderson's and other Asiatic red-backed voles.

7.
Pain Ther ; 10(1): 711-727, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33856660

ABSTRACT

INTRODUCTION: Mirogabalin, which is a selective ligand of the α2δ subunit of voltage-gated Ca2+ channels, was recently approved in Japan for peripheral neuropathic pain. The α2δ ligands, including mirogabalin and pregabalin, are associated with significant risk of adverse events (AEs) such as somnolence or dizziness, leading to poor compliance and subsequent inefficacy. Safety and efficacy data for switching patients from pregabalin to mirogabalin are scarce. METHODS: This prospective, single-arm, open-label study involving ten participating centers in Japan recruited patients aged ≥ 20 years with peripheral neuropathic pain [visual analog scale (VAS) score ≥ 40 mm]. Where necessary, patients underwent a 1-week tapering period to reduce their pregabalin dose, after which pregabalin was stopped and mirogabalin dose was increased using a step-wise dose titration. Patients underwent dose increases after the first and second weeks if there were no tolerability issues, followed by the effective doses until the end of the study (4 weeks). The primary endpoint was the incidence of somnolence, dizziness, and peripheral edema; secondary endpoints included changes in VAS score. AEs were monitored for safety. RESULTS: Of 157 patients who provided informed consent, 152 patients were enrolled; 136 (89.5%) patients completed the study. The overall incidences of somnolence, dizziness, and peripheral edema were 41.4, 15.8, and 2.6%, respectively. Most patients (> 70%) experienced mild AEs, and one patient experienced a severe AE (dizziness). Most patients (> 70%) were able to achieve dose titration to an effective dose. Overall mean VAS score significantly decreased (Δ15.7 mm, p < 0.0001) by the end of the study. CONCLUSIONS: Mirogabalin switching from pregabalin is well tolerated and effective in pain management for peripheral neuropathic pain using a step-wise titration. TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCTs031190113).

8.
J Neurosurg Anesthesiol ; 33(1): 58-64, 2021 Jan.
Article in English | MEDLINE | ID: mdl-31290770

ABSTRACT

BACKGROUND: Prolongation of the interval from the peak to the end of the T wave (Tp-Te) on a 12-lead electrocardiogram (ECG) is associated with ventricular arrhythmias. The aim of this study was to clarify associations between Tp-Te, Tp-Te/QT, and Tp-Te/rate-corrected QT (QTc) with clinical severity of subarachnoid hemorrhage (SAH) and clinical outcomes. METHODS: This retrospective study included 222 patients with acute SAH (group S) and 306 patients with unruptured cerebral aneurysms (group U). Tp-Te, Tp-Te/QT, and Tp-Te/QTc were manually measured in standard 12-lead ECG recordings on admission and comparisons made between patients in groups S and U. The relationships of these ECG parameters with Hunt and Hess grade and Glasgow outcome scale were analyzed using multiple logistic regression analysis after adjustment for confounding factors. RESULTS: Tp-Te, Tp-Te/QT, and Tp-Te/QTc were significantly greater in group S than in group U (group S: 109±30, 0.26±0.07, and 0.24±0.06 ms; group U: 84±12, 0.22±0.03, and 0.21±0.03 ms, respectively; P < 0.0001). In addition, in the multiple logistic regression analyses these variables were positively correlated with the Hunt and Hess grade (Tp-Te odds ratio [95% confidence interval], 2.414 [1.375-4.238], P=0.002; Tp-Te/QT, 1.886 [1.085-3.277], P = 0.024; Tp-Te/QTc, 1.873 [1.07-3.278], P=0.028, and negatively correlated with Glasgow outcome scale Tp-Te odds ratio [95% confidence interval], 4.168 [2.409-7.209], P<0.001; Tp-Te/QT, 2.434 [1.413-4.192], P=0.001; Tp-Te/QTc 2.953 [1.703-5.123], P<0.001). CONCLUSIONS: Tp-Te, Tp-Te/QT, and Tp-Te/QTc are associated with disease severity and clinical outcome in patients with SAH.


Subject(s)
Arrhythmias, Cardiac/complications , Arrhythmias, Cardiac/physiopathology , Electrocardiography/methods , Subarachnoid Hemorrhage/complications , Female , Humans , Male , Middle Aged , Retrospective Studies , Severity of Illness Index
9.
Eur J Pharmacol ; 886: 173445, 2020 Nov 05.
Article in English | MEDLINE | ID: mdl-32758571

ABSTRACT

The incidence of colon cancer increased worldwide in 2019 and its treatment is urgent from a quality of life perspective. A relationship has been reported between elevated numbers of tumor-associated macrophages (TAMs) in the tumor microenvironment and a poor prognosis in cancer patients, and M2 TAMs have been shown to promote tumor growth by immunosuppression through the stimulation of programmed death-1 (PD-1, an immune check point receptor), interleukin (IL)-1ß, and monocyte chemoattractant protein (MCP)-1. We herein examined the effects of three synthetic dihydroxystilbenes (2,3-, 3,4-, and 4,4'-dihydroxystilbenes) on colon carcinogenesis, colon tumor growth, and colon cytokines (IL-1ß, IL-6, and tumor necrosis factor (TNF)-α), a chemokine (MCP-1), vascular endothelial growth factor (VEGF), and PD-1 levels in azoxymethane (AOM) plus dextran sulfate sodium (DSS)-treated C57BL/6J mice. The three dihydroxystilbenes inhibited colon carcinogenesis and tumor growth as well as increases in colon IL-1ß, IL-6, MCP-1, and PD-1 levels in AOM/DDS-treated mice (in vivo). The three dihydroxystilbenes also suppressed COX-2 expression in colon tumors (in vivo). The results obtained also revealed that the three dihydroxystilbenes inhibited PD-1 elevations in M2-THP-1 macrophages (in vitro). Therefore, the inhibition of AOM/DSS-induced colon carcinogenesis and colon tumor growth by 2,3-, 3,4-, and 4,4'-dihydroxystilbenes appears to be due to the suppression of M2 TAM differentiation and activation and PD-1 expression (immunosuppression) via reductions in COX-2 expression levels in the colon tumor microenvironment.


Subject(s)
Apoptosis/drug effects , Chemokines/antagonists & inhibitors , Colonic Neoplasms/chemically induced , Colonic Neoplasms/prevention & control , Cytokines/antagonists & inhibitors , Dihydrostilbenoids/therapeutic use , Animals , Azoxymethane , Carcinogens/antagonists & inhibitors , Chemokine CCL2/drug effects , Colonic Neoplasms/metabolism , Cyclooxygenase 2 Inhibitors/pharmacology , Dextran Sulfate , Dihydrostilbenoids/chemical synthesis , Dihydrostilbenoids/chemistry , Humans , Macrophages/drug effects , Macrophages/metabolism , Male , Mice , Mice, Inbred C57BL , Tumor Microenvironment/drug effects
10.
Cardiol Ther ; 7(2): 163-172, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30218410

ABSTRACT

INTRODUCTION: Reversal of non-depolarizing neuromuscular blocking agent neostigmine is associated with QT prolongation under general anesthesia. To clarify the effects of neostigmine and sugammadex on hemodynamic status, the QT interval and QT dispersion after reversal of neuromuscular blockade were evaluated with a 12-lead electrocardiogram. To exclude QT prolongation due to sevoflurane, the present study was performed under propofol anesthesia. METHODS: After receiving approval from the ethics committee of Dokkyo Medical University Hospital, 40 patients with American Society of Anesthesiologists physical status I or II were randomly allocated to group N (n = 20) or group S (n = 20). Group N was administered neostigmine (40 µg/kg) and atropine (20 µg/kg), while Group S was administered sugammadex (4 mg/kg) for reversal of neuromuscular blockade after surgery. The changes in RR interval, QT interval (QT), corrected QT interval (QTc), QT dispersion (QTD), and corrected QT dispersion (QTcD) before and after administration of reversal agents were recorded using computerized measurements. Statistical analysis was performed using two-way analysis of variance. RESULTS: The RR interval significantly decreased after reversal of the neuromuscular blockade in group N, compared with group S (p < 0.05). Compared with group S, the QT decreased, whereas QTc and QTcD increased, in group N (p < 0.05). Sugammadex was not found to alter QT, QTc, QTD, or QTcD throughout the study. CONCLUSION: In the present study, a mixture of neostigmine and atropine, but not sugammadex, increased QTc and QTcD under propofol anesthesia. Thus, neostigmine may cause electrocardiogram abnormalities that could precede the development of fatal arrhythmias.

11.
Nutr Cancer ; 68(4): 667-78, 2016.
Article in English | MEDLINE | ID: mdl-27145432

ABSTRACT

Antitumor and antimetastatic effects of resveratrol on tumor-induced lymphangiogenesis through the regulation of M2 macrophages in tumor-associated macrophages currently remain unknown. Therefore, we herein examined the effects of resveratrol on M2 macrophage activation and differentiation, and those of resveratrol-treated condition medium (CM) in M2 macrophages on vascular endothelial cell growth factor (VEGF)-C-induced migration, invasion, and tube formation by human lymphatic endothelial cells (HLECs). Resveratrol (50 µM or 5-50 µM) inhibited the production of interleukin-10 and monocyte chemoattractant protein-1 in M2 macrophages, whereas it promoted that of transforming growth factor-ß1. Resveratrol (25 and 50 µM) inhibited the phosphorylation of signal transducer and activator of transcript 3 without affecting its expression in the differentiation process of M2 macrophages. Furthermore, resveratrol-treated CM of M2 macrophages inhibited VEGF-C-induced HLEC migration, invasion, and lymphangiogenesis. Resveratrol (25 mg/kg, twice daily) inhibited tumor growth and metastasis to the lung and also reduced the area of lymphatic endothelial cells in tumors (in vivo). These results suggest that the antitumor and antimetastatic effects of resveratrol were partly due to antilymphangiogenesis through the regulation of M2 macrophage activation and differentiation.


Subject(s)
Bone Neoplasms/pathology , Lymphangiogenesis/drug effects , Macrophages/pathology , Osteosarcoma/pathology , Stilbenes/pharmacology , Animals , Antineoplastic Agents, Phytogenic/pharmacology , Bone Neoplasms/drug therapy , Cell Differentiation/drug effects , Cell Line, Tumor , Cell Movement/drug effects , Chemokine CCL2/metabolism , Humans , Interleukin-10/metabolism , Macrophage Activation/drug effects , Macrophages/drug effects , Macrophages/metabolism , Male , Mice, Inbred C3H , Osteosarcoma/drug therapy , Resveratrol , STAT3 Transcription Factor/metabolism , Transforming Growth Factor beta1/metabolism , Xenograft Model Antitumor Assays
12.
Nutr Cancer ; 68(5): 791-803, 2016 07.
Article in English | MEDLINE | ID: mdl-27046042

ABSTRACT

We herein compared the effects of the chronic feeding of high-fat (HF), high-sucrose (HS), and low-fat/low-sucrose (control) diets on carcinogenesis following chronic ultraviolet B (UVB) irradiation in hairless mice. UVB irradiation-induced carcinogenesis was more prominent in HF diet-fed group than in control diet- and HS diet-fed groups. The HS diet group, as well as the HF diet one, showed tumor development and growth, increased skin matrix metalloproteinase (MMP) and blood plasminogen activator inhibitor-1 (PAI-1) levels, and decreased blood leptin and adiponectin levels after long-term UVB irradiation. These changes were smaller in the HS diet group than in the HF diet group. In addition, no difference was noted in the above changes between the control and HS diet groups. The increase induced in adipose tissue weight by the HF diet was markedly reduced by UVB irradiation. This result suggests that the abundant availability of lipids in hypertrophic adipose tissue may be related to tumor incidence and growth through increases in blood PAI-1 and skin MMP-9 expression levels and decreases in blood adiponectin levels by UVB irradiation. In conclusion, HF diet-induced hypertrophic adipose tissue is an important cancer risk factor that promotes UV irradiation-induced carcinogenesis and tumor growth.


Subject(s)
Carcinogenesis/radiation effects , Diet, High-Fat/adverse effects , Dietary Sucrose/adverse effects , Ultraviolet Rays/adverse effects , Adiponectin/blood , Animals , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/radiation effects , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/radiation effects , Chemokine CCL2/blood , Insulin/blood , Leptin/blood , Male , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/metabolism , Mice , Mice, Hairless , Mice, Inbred C57BL , Risk Factors , Serpin E2/blood , Skin/drug effects , Skin/metabolism , Skin/radiation effects
13.
Anticancer Res ; 36(1): 137-48, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26722037

ABSTRACT

An increase in tumor-associated macrophages (TAMs) around the tumor microenvironment has been closely associated with a poor prognosis in patients with cancer, and M2 TAMs promote tumor growth and tumor metastasis by stimulating angiogenesis or lymphangiogenesis in tumors. We herein examined the effects of nine synthetic hydroxystilbenes on M2 macrophage activation and differentiation, and three selected dihydroxystilbenes on vascular endothelial cell growth factor (VEGF)-C-induced tube formation in human lymphatic endothelial cells (HLECs) (in vitro). We also investigated the antitumor and antimetastatic effects of three synthetic dihydroxystilbenes in LM8-bearing mice in vivo. The three selected synthetic stilbenes (at concentrations of 5, 10, 25, and 50 µM) inhibited the production of interleukin-10 and monocyte chemoattractant protein-1 in M2 macrophages, but promoted that of transforming growth factor-ß1. The three dihydroxystilbenes (at concentrations of 10-50 µM) inhibited the phosphorylation of signal transducer and activator of transcript 3 without affecting its expression in the differentiation of M2 macrophages. Furthermore, the 2,3- and 4,4'-dihydroxystilbene inhibited VEGF-C-induced lymphangiogenesis in HLECs. Both 2,3- and 4,4'-dihydroxystilbene (at 10 and 25 mg/kg, twice daily) inhibited tumor growth and metastasis to the lung in mice. These results suggested that the antitumor and antimetastatic effects of 2,3- and 4,4'-dihydroxystilbene were partly due to anti-lymphangiogenesis, and the regulation of M2 macrophage activation and differentiation.


Subject(s)
Antineoplastic Agents/pharmacology , Bone Neoplasms/drug therapy , Cell Differentiation/drug effects , Lung Neoplasms/prevention & control , Lymphangiogenesis/drug effects , Lymphatic Vessels/drug effects , Macrophages/drug effects , Osteosarcoma/drug therapy , Stilbenes/pharmacology , Animals , Antineoplastic Agents/chemical synthesis , Bone Neoplasms/metabolism , Bone Neoplasms/pathology , Cell Line, Tumor , Chemokine CCL2/metabolism , Dose-Response Relationship, Drug , Humans , Interleukin-10/metabolism , Lung Neoplasms/metabolism , Lung Neoplasms/secondary , Lymphatic Vessels/metabolism , Lymphatic Vessels/pathology , Macrophage Activation/drug effects , Macrophages/metabolism , Macrophages/pathology , Male , Mice, Inbred C3H , Osteosarcoma/metabolism , Osteosarcoma/secondary , Phenotype , Phosphorylation , STAT3 Transcription Factor/metabolism , Signal Transduction/drug effects , Stilbenes/chemical synthesis , Transforming Growth Factor beta1/metabolism , Tumor Microenvironment , Vascular Endothelial Growth Factor C/pharmacology , Xenograft Model Antitumor Assays
14.
Nat Prod J ; 6(1): 49-55, 2016 Mar.
Article in English | MEDLINE | ID: mdl-28553575

ABSTRACT

OBJECTIVE: The root and stem barks of Eleutherococcus senticosus have been used to treat emotional and physical fatigue in China, Russia, Korea, and Japan. The effects of E. senticosus on recovery from physical fatigue and the expenditure of energy currently remain unclear. We herein examined the effects of E. senticosus extract on recovery from physical fatigue after the forced swimming test as well as fatty acid ß-oxidation in the liver and skeletal muscle of mice. METHODS: 1) Physical fatigue; E. senticosus extract (500 and 1000 mg/kg, twice daily) was administered orally to ICR male mice for 7 consecutive days. After swimming had been performed for 15 min, each mouse was placed on the cover of a 100-mm culture plate, and the time for each mouse to move away from the cover was measured. 2) Fatty acid ß-oxidation in the liver and skeletal muscle; E. senticosus extract (500 and 1000 mg/kg) was administered orally twice daily to C57BL/6J male mice for 21 consecutive days. The initial and final body and liver weight were measured, and then fatty acid ß-oxidation activity in the liver and skeletal muscle was measured by methods using [1-14C] palmitic acid. KEY FINDINGS: Recovery times after forced swimming were shorter in E. senticosus extract (500 and 1000 mg/kg)-treated mice than in vehicle-treated mice. The body and liver weight had no effect by the oral administration of E. senticosus extract, vitamin mixture and L-carnitine. Fatty acid ß-oxidation activity in skeletal muscle was increased by E. senticosus extract (500 and 1000 mg/kg). CONCLUSION: E. senticosus may enhance recovery from physical fatigue induced by forced swimming by accelerating energy changes through fatty acid ß-oxidation in skeletal muscle.

15.
Phytomedicine ; 22(7-8): 759-67, 2015 Jul 15.
Article in English | MEDLINE | ID: mdl-26141763

ABSTRACT

BACKGROUND: Tumor growth and metastasis have been closely associated with the M2 macrophage-induced activation of tumor-associated macrophages (TAMs). PURPOSE: The antitumor and antimetastatic actions of xanthangelol and 4-hydroxyderricin on the role of M2 macrophages in the TAMs of highly metastatic osteosarcoma LM8-bearing mice have not yet been fully elucidated. In order to clarify the mechanisms underlying the antitumor and antimetastatic actions of the above chalcones, we performed in vivo and in vitro studies. STUDY DESIGN: The antitumor and antimetastatic actions of xanthoangelol and 4-hydroxyderricin were examined in vivo and the effects on M2 macrophage differentiation and activation were examined in vitro. METHODS: We examined the antitumor and antimetastatic effects of xanthoangelol and 4-hydroxyderricin on highly metastatic osteosarcoma LM8-bearing mice (in vivo). Further, we examined their effects on the differentiation of interleukin (IL)-4 plus IL-13-induced M2 macrophages and activation of IL-4 plus IL13-induced M2 macrophages (in vitro). We also investigated the expression and phosphorylation of signal transducer and activator of transcript 3 (Stat 3) in the differentiation process of M2-polarized macrophages (in vitro). RESULTS: Xanthoangelol or 4-hydroxyderricin (25 or 50 mg/kg, twice daily) inhibited tumor growth, metastasis to the lung and liver, and TAM expression in tumors. In addition, xanthoangelol (10, 25 or 50 µM) and 4-hydroxyderricin (5, 10, 25 or 50 µM) inhibited the production of IL-10 and monocyte chemoattractant protein (MCP)-1 in M2-polarized macrophages. This result indicated that xanthoangelol and 4-hydroxyderricin inhibited the activation of M2 macrophages. Furthermore, xanthoangelol (5-50 µM) inhibited the phosphorylation of Stat 3 without affecting the expression of the Stat 3 protein in the differentiation process of M2 macrophages, which indicated that these chalcones inhibited the differentiation of M2 macrophages. CONCLUSION: These findings suggested that the antitumor and antimetastatic actions of xanthoangelol and 4-hydroxyderrcin might be attributed to the regulated activated TAMs through the inhibition of activation and differentiation of M2 macrophages in the tumor microenvironment.


Subject(s)
Angelica/chemistry , Anticarcinogenic Agents/pharmacology , Antineoplastic Agents, Phytogenic/pharmacology , Chalcone/analogs & derivatives , Macrophages/drug effects , Animals , Cell Differentiation/drug effects , Cell Line , Chalcone/pharmacology , Chemokine CCL2/metabolism , Disease Models, Animal , Humans , Interleukin-10/metabolism , Macrophage Activation/drug effects , Male , Mice, Inbred C3H , Osteosarcoma/pathology , Plant Roots/chemistry , STAT3 Transcription Factor/metabolism
16.
Eur J Pharmacol ; 746: 115-25, 2015 Jan 05.
Article in English | MEDLINE | ID: mdl-25445053

ABSTRACT

Tumor growth and metastasis are closely associated with the M2 macrophage activation of tumor-associated macrophages (TAMs) in the tumor microenvironment as well as the development of tumor cells. In this study, we examined the antiproliferative, antitumor, and antimetastatic effects of three dihydroxycoumarins (esculetin, fraxetin, and daphnetin) against osteosarcoma LM8 cells (in vitro) and a highly metastatic model in LM8-bearing mice (in vivo). Esculetin (20-100µM) inhibited the proliferation of LM8 cells, whereas fraxetin and daphnetin had no effect. Esculetin inhibited the expressions of cyclin D1, cyclin-dependent kinase (CDK) 4 and matrix metalloproteinase (MMP)-2, and production of both transforming growth factor (TGF)-ß1 and vascular endothelial growth factor (VEGF) in LM8 cells. Esculetin (3 or 10mg/kg) and fraxetin (10mg/kg) inhibited tumor growth and metastasis to the lung or liver, whereas daphnetin did not. These results suggested that the antitumor and antimetastatic actions of esculetin may be partly attributed to G1 arrest by the inhibition of cyclin D1 and CDK4 expression, while its antiangiogenic action may have been due to the inhibition of MMP-2 expression and TGF-ß1 and VEGF productions at tumor sites. Esculetin (10-100µM) and fraxetin (50-100µM) inhibited the production of interleukin (IL)-10, monocyte chemoattractant protein (MCP)-1, and TGF-ß1 during the differentiation of M2 macrophages by reducing the phosphorylation of Stat 3 without affecting its expression. These results also suggested that the antitumor and antimetastatic actions of esculetin or fraxetin may be due to the regulated activation of TAM by M2 macrophage differentiation in the tumor microenvironment.


Subject(s)
Cell Differentiation/drug effects , Coumarins/pharmacology , G1 Phase Cell Cycle Checkpoints/drug effects , Macrophages/cytology , Macrophages/drug effects , Osteosarcoma/pathology , Umbelliferones/pharmacology , Animals , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Body Weight/drug effects , Cell Line, Tumor , Cell Polarity/drug effects , Cell Proliferation/drug effects , Chemokine CCL2/biosynthesis , Cyclin-Dependent Kinase 4/metabolism , Gene Expression Regulation, Neoplastic/drug effects , Humans , Interleukin-10/biosynthesis , Macrophage Activation/drug effects , Male , Matrix Metalloproteinase 2/metabolism , Mice , Neoplasm Metastasis , STAT3 Transcription Factor/metabolism , Tetradecanoylphorbol Acetate/pharmacology , Transforming Growth Factor beta1/biosynthesis , Vascular Endothelial Growth Factor A/biosynthesis , Xenograft Model Antitumor Assays
17.
J Nat Med ; 68(1): 83-94, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23649674

ABSTRACT

We examined the effects on cell proliferation of 10 methoxyfurocoumarins and 7 dihydrofurocumarins isolated from Umbelliferae medicinal plants, and their mechanisms of action against B16F10 melanoma cells or in melanin-possessing hairless mice implanted with B16F10 melanoma cells, under UVA irradiation. Furocoumarins having a methoxy group, such as bergapten (1), xanthotoxin (2), phellopterin (4), byakangelicin (6), neobyakangelicin (8), isobergapten (9) and sphondin (10), showed anti-proliferative activity and caused G2/M arrest at concentrations of 0.05-15.0 µM. The 7 dihydrofurocoumarins had no effect. UVA plus 1, 2, 4, 6 and sec-O-acetylbyakagelicin (7), having one methoxy group at the C-5 position and a linear-type conformation, reduced tumor growth and final tumor weight in B16F10-bearing mice at 0.5 or 1.0 mg/kg (intraperitoneal injection). UVA plus 1 and 2 increased Chk1 phosphorylation and decreased cdc2 (Thr 161) phosphorylation in the melanoma cells. The anti-tumor actions of UVA plus furocoumarins having a methoxy group might be due to the arrest of the cell cycle at G2/M through an increase in phospho-Chk1 and reduction in phospho-cdc2.


Subject(s)
Angelica , Cnidium , Furocoumarins/pharmacology , Melanoma, Experimental/drug therapy , PUVA Therapy , Radiation-Sensitizing Agents/pharmacology , Angelica/chemistry , Animals , CDC2 Protein Kinase/metabolism , Cell Proliferation/drug effects , Checkpoint Kinase 1 , Cnidium/chemistry , Dose-Response Relationship, Drug , Fruit , Furocoumarins/isolation & purification , G2 Phase Cell Cycle Checkpoints/drug effects , Inhibitory Concentration 50 , Male , Melanoma, Experimental/metabolism , Melanoma, Experimental/pathology , Mice , Mice, Hairless , Phosphorylation , Phytotherapy , Plant Roots , Plants, Medicinal , Protein Kinases/metabolism , Radiation-Sensitizing Agents/isolation & purification , Seeds , Tumor Burden/drug effects , Ultraviolet Rays
18.
J Nutr ; 144(1): 27-32, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24174624

ABSTRACT

Whey proteins or peptides exhibit various actions, including an antioxidant action, an anticancer action, and a protective action against childhood asthma and atopic syndrome. The effects of orally administered whey peptides (WPs) on chronic ultraviolet B (UVB) radiation-induced cutaneous changes, including changes in cutaneous thickness, elasticity, wrinkle formation, etc., have not been examined. In this study, we studied the preventive effects of WPs on cutaneous aging induced by chronic UVB irradiation in melanin-possessing male hairless mice (HRM). UVB (36-180 mJ/cm(2)) was irradiated to the dorsal area for 17 wk in HRM, and the measurements of cutaneous thickness and elasticity in UVB irradiated mice were performed every week. WPs (200 and 400 mg/kg, twice daily) were administered orally for 17 wk. WPs inhibited the increase in cutaneous thickness, wrinkle formation, and melanin granules and the reduction in cutaneous elasticity associated with photoaging. Furthermore, it has been reported that UVB irradiation-induced skin aging is closely associated with the increase in expression of matrix metalloproteinase (MMP), vascular endothelial growth factor (VEGF), Ki-67-, and 8-hydroxy-2'-deoxyguanosine (8-OHdG)-positive cells. WPs also prevented increases in the expression of MMP-2 and pro-MMP-9, VEGF, and Ki-67- and 8-OHdG-positive cells induced by chronic UVB irradiation. It was found that WPs prevent type IV collagen degradation, angiogenesis, proliferation, and DNA damage caused by UVB irradiation. Overall, these results demonstrate the considerable benefit of WPs for protection against solar UV-irradiated skin aging as a supplemental nutrient.


Subject(s)
Dietary Supplements , Milk Proteins/administration & dosage , Skin Aging/drug effects , Skin Aging/radiation effects , Ultraviolet Rays/adverse effects , 8-Hydroxy-2'-Deoxyguanosine , Administration, Oral , Animals , Antioxidants/administration & dosage , Blood Vessels/drug effects , Blood Vessels/metabolism , Collagen Type IV/metabolism , DNA Damage/radiation effects , Deoxyguanosine/analogs & derivatives , Deoxyguanosine/metabolism , Enzyme Precursors/genetics , Enzyme Precursors/metabolism , Ki-67 Antigen/genetics , Ki-67 Antigen/metabolism , Male , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 2/metabolism , Matrix Metalloproteinase 9/genetics , Matrix Metalloproteinase 9/metabolism , Mice , Mice, Hairless , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism , Whey Proteins
19.
Photochem Photobiol ; 89(5): 1216-25, 2013.
Article in English | MEDLINE | ID: mdl-23802687

ABSTRACT

We examined the effects of six furocoumarins with alkoxy groups at the C-5 or C-8 position isolated from Umbelliferae medicinal plants on cell proliferation, and their mechanisms of action against B16F10 melanoma cells or in melanin-possessing hairless mice implanted with B16F10 cells, under UVA irradiation. Three furocoumarins with an alkoxy group at C-5, isoimperatorin (1), oxypeucedanin (2) and oxypeucedanin hydrate (3), showed antiproliferative activity and caused G2/M arrest at concentrations of 0.1-10.0 µm. Furthermore, three furocoumarins with an alkoxy group at C-8, imperatorin (4), heraclenin (5) and heraclenol (6), inhibited the proliferation of melanoma cells and cell cycle at G2/M at concentrations of 0.1-1.0 µm. UVA plus 1, 2, 3, 4 and 6 reduced tumor growth and final tumor weight in B16F10-bearing mice at a dose of 0.3, 0.5 or 1.0 mg kg(-1) (intraperitoneal injection). UVA plus 1, 3 and 6 increased Chk1 phosphorylation and reduced cdc2 (Thr 161) phosphorylation in melanoma cells. We suggest that the antitumor actions of UVA plus furocoumarins with an alkoxy group at C-5 or C-8 were due to G2/M arrest of the cell cycle by an increase in phosphor-Chk1 and decrease in phospho-cdc2.


Subject(s)
Apiaceae/chemistry , Cell Proliferation/drug effects , Cell Proliferation/radiation effects , Furocoumarins/pharmacology , Melanoma, Experimental/pathology , Plants, Medicinal/chemistry , Ultraviolet Rays , Animals , Furocoumarins/isolation & purification , In Vitro Techniques , Mice , Mice, Hairless
20.
Fitoterapia ; 84: 163-9, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23160092

ABSTRACT

The Curcuma zedoaria rhizome has been used traditionally to treat gastrointestinal diseases as an aromatic stomachic drug, and this is currently used to treat alcohol-induced loss of appetite and nausea in Japan. We examined the effects of various fractions and isolated compounds on alcohol-induced drunkenness and blood alcohol concentrations in mice. The 30% ethanol-extract (1000mg/kg) of C. zedoaria rhizome prevented drunkenness 60 and 120min after 40% alcohol administration. The n-hexane-soluble fraction (300mg/kg) and an isolated compound (3, 10 or 30mg/kg) prevented drunkenness at 30, 60 or 120min. The extract, n-hexane-soluble fraction and isolated compound reduced the elevation in blood alcohol concentrations 30 and 60min after 40% alcohol administration. The isolated compound (10 and 30mg/kg) enhanced liver ADH activity 30 and 60min after 40% alcohol administration. The compound was identified as curcumenone by a direct comparison of (1)H- and (13)C-NMR spectral data. In conclusion, the protective effect of the C. zedoaria extract on drunkenness might be due to an active substance, curcumenone, and decreases in the elevation of blood alcohol concentrations through increased liver alcohol dehydrogenase activity.


Subject(s)
Curcuma/chemistry , Ethanol/toxicity , Plant Extracts/pharmacology , Rhizome/chemistry , Administration, Oral , Alcohol Dehydrogenase/genetics , Alcohol Dehydrogenase/metabolism , Animals , Dose-Response Relationship, Drug , Liver/enzymology , Male , Mice , Mice, Inbred ICR , Plant Extracts/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...